GSA/FDA Dedicate Center for Drug Evaluation And Research (CDER) Office Building I in White Oak, Maryland
Posted on: Tuesday, 12 July 2005, 12:01 CDT
WASHINGTON, July 12 /PRNewswire/ -- The U.S. General Services Administration (GSA), in partnership with the Food and Drug Administration (FDA), celebrated today the completion of construction for the Center for Drug Evaluation and Research (CDER) Office Building I at the Federal Research Center in White Oak, Maryland. GSA Administrator Stephen Perry, Secretary of Health & Human Services Michael Leavitt, Acting FDA Commissioner Lester Crawford, Senators Orrin Hatch of Utah, Paul Sarbanes and Barbara Mikulski of Maryland; Representatives Steny Hoyer and Albert Wynn; and Maryland Lieutenant Governor Michael Steele participated in the ceremony, which was hosted by Donald C. Williams, Regional Administrator for GSA's National Capital Region.
"We are pleased to be taking another step toward the completion of this great facility," commented Donald C. Williams, Regional Administrator for GSA's National Capital Region (NCR), "as the White Oak campus becomes the premier research complex in America for insuring the safety of our food and medications."
With 551,000 gross square feet of office space, the new building will accommodate CDER's Office of New Drug Evaluation and its support functions, housing 1,750 people. It will be the largest facility in the complex, designed with five wings so that all offices have exterior windows and natural daylight permeates virtually all parts of the building.
In addition to headquarters for the Center for Drug Evaluation and Research (CDER), the new campus will house FDA's Center for Devices and Radiological Health (CDRH), Center for Biological Evaluation and Research (CBER), Office of Regulatory Affairs (ORA) and Office of the Commissioner (OC). The project totals 3.1 million gross square feet of office and lab space, consolidating FDA activities currently housed in 48 leased locations throughout suburban Maryland. Campus buildings will be grouped into clusters that are linked together by covered walkways. Subsequent phases, which are scheduled for completion by the end of 2010, are either in the design stage or scheduled for future funding by Congress.
U.S. General Services Administration, National Capital Region
CONTACT: Michael McGill of the U.S. General Services Administration,National Capital Region, +1-202-205-1624
Web site: http://www.gsa.gov/
Source: PRNewswire
Related Articles
- New FDA Research Center Rife With Risks
- BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration on Biomarker Discovery for MS Disease Activity and Drug Response
- Sidra Medical & Research Center's Sparkling Design Incorporates Nature to Promote Healing
- EPIX Pharmaceuticals Files Formal Appeal for Vasovist(TM) With the Center for Drug Evaluation and Research
- GSK Plans to Establish Three Research Centers
- EPIX Pharmaceuticals to File Appeal With the Center for Drug Evaluation and Research for Vasovist(TM)
- Statement of Diana Zuckerman, PhD, President, National Research Center for Women & Families
- Invitrogen and the National Center for Drug Screening (Shanghai) Announce Collaborative Research Agreement
- FDA's New Center for Drug Evaluation and Research Office Bldg. To Be Dedicated Today
- GSA/FDA to Dedicate Center for Drug Evaluation and Research (CDER) Office Building I in White Oak, Maryland
 |
 |
User Comments (0)
RSS Feeds